Ferraresi Martina, Pia Anna, Guzzo Gabriella, Vigotti Federica Neve, Mongilardi Elena, Nazha Marta, Aroasio Emiliano, Gonella Cinzia, Avagnina Paolo, Piccoli Giorgina Barbara
Nephrology Unit, Department of Clinical and Biological Sciences, San Luigi Gonzaga Hospital, University of Torino.
Laboratory, Department of Clinical and Biological Sciences, San Luigi Gonzaga Hospital, University of Torino.
Hemodial Int. 2015 Oct;19(4):572-82. doi: 10.1111/hdi.12296. Epub 2015 Mar 26.
Severe hyperparathyroidism is a challenge on hemodialysis. The definition of dialysate calcium (Ca) is a pending issue with renewed importance in cases of individualized dialysis schedules and of portable home dialysis machines with low-flow dialysate. Direct measurement of calcium mass transfer is complex and is imprecisely reflected by differences in start-to-end of dialysis Ca levels. The study was performed in a dialysis unit dedicated to home hemodialysis and to critical patients with wide use of daily and tailored schedules. The Ca-phosphate (P)-parathyroid hormone (PTH) profile includes creatinine, urea, total and ionized Ca, albumin, sodium, potassium, P, PTH levels at start, mid, and end of dialysis. "Severe" secondary hyperparathyroidism was defined as PTH > 300 pg/mL for ≥3 months. Four schedules were tested: conventional dialysis (polysulfone dialyzer 1.8-2.1 m(2) ), with dialysate Ca 1.5 or 1.75 mmol/L, NxStage (Ca 1.5 mmol/L), and NxStage plus intradialytic Ca infusion. Dosages of vitamin D, calcium, phosphate binders, and Ca mimetic agents were adjusted monthly. Eighty Ca-P-PTH profiles were collected in 12 patients. Serum phosphate was efficiently reduced by all techniques. No differences in start-to-end PTH and Ca levels on dialysis were observed in patients with PTH levels < 300 pg/mL. Conversely, Ca levels in "severe" secondary hyperparathyroid patients significantly increased and PTH decreased during dialysis on all schedules except on Nxstage (P < 0.05). Our data support the need for tailored dialysate Ca content, even on "low-flow" daily home dialysis, in "severe" secondary hyperparathyroid patients in order to increase the therapeutic potentials of the new dialysis techniques.
重度甲状旁腺功能亢进是血液透析中的一项挑战。在个体化透析方案以及使用低流量透析液的便携式家庭透析机的情况下,透析液钙(Ca)的定义是一个重新变得重要的悬而未决的问题。直接测量钙的质量传递很复杂,并且透析开始至结束时Ca水平的差异并不能精确反映这一过程。该研究在一个专门进行家庭血液透析以及广泛使用每日和定制透析方案的重症患者的透析单元中进行。钙 - 磷(P) - 甲状旁腺激素(PTH)谱包括透析开始、中间和结束时的肌酐、尿素、总钙和离子钙、白蛋白、钠、钾、P、PTH水平。“重度”继发性甲状旁腺功能亢进定义为PTH≥300 pg/mL持续≥3个月。测试了四种方案:常规透析(聚砜透析器1.8 - 2.1 m²),透析液Ca为1.5或1.75 mmol/L,NxStage(Ca 1.5 mmol/L),以及NxStage加透析中钙输注。维生素D、钙、磷结合剂和钙模拟剂的剂量每月调整一次。收集了12例患者的80份钙 - 磷 - PTH谱。所有技术均能有效降低血清磷。PTH水平<300 pg/mL的患者在透析过程中开始至结束时的PTH和Ca水平没有差异。相反,在“重度”继发性甲状旁腺功能亢进患者中,除NxStage方案外,所有方案在透析过程中Ca水平显著升高而PTH降低(P<0.05)。我们的数据支持在“重度”继发性甲状旁腺功能亢进患者中,即使是在“低流量”每日家庭透析中,也需要定制透析液Ca含量,以提高新透析技术的治疗潜力。